IGMS - IGM Biosciences starts phase 1 trial of antibody therapy for solid tumors

• IGM Biosciences ( NASDAQ: IGMS ) said the first patient was dosed in a phase 1 trial of IGM-7354 for solid tumors.
• IGM-7354 is a targeted IL-15/IL-15R IgM antibody which could potentially be used to treat patients with solid tumors and blood cancers.
• The study will evaluate IGM-7354 intravenously administered as a monotherapy in patients with relapsed and/or refractory solid tumor cancers.
• If the drug shows an encouraging safety and significant increases in T cells and natural killer (NK) cells, the company may start combination studies of IGM-7354 with T cell engaging antibodies in 2024, according to IGM Biosciences.
• The company noted that it may also decide to pursue combination studies with CAR-T or CAR-NK cells with a partner.
• "The initiation of this clinical trial is another significant milestone in IGM’s development, as it is the first clinical study of an IgM targeted immune cytokine," said IGM Biosciences CEO Fred Schwarzer.
• IGMS -3.47% to $24.45 premarket

For further details see: